🔍 What caught our attention about TRI-611?

Not just that it's the first clinical-stage ALK molecular glue degrader.
It's the discovery of a novel turn-helix degron interface that enables near-complete degradation of ALK through CRBN recruitment.

Sometimes, the biggest breakthroughs come from finding entirely new ways to engage a target.
ChemScene is proud to support molecular glue discovery with a diverse portfolio of CRBN ligand building blocks.

🌐 www.arctomsci.com
#MolecularGlue #TargetedProteinDegradation #CRBN #ALK #DrugDiscovery #ChemScene

Originally posted on LinkedIn: 2026-10-15 (UTC; date derived from the LinkedIn activity ID).

Source: ChemScene on LinkedIn